Novotech to support Beijing Biostar’s clinical R&D efforts
Australian CRO Novotech has teamed up with oncology-focused, synthetic biology developer Beijing Biostar Pharmaceuticals.
The accord – financial terms of which were not provided – will see Novotech support Biostar’s clinical development and market expansion plan, according to Andy Liu, general manager of Novotech China.
“As a strategic partner in Biostar’s research phase, we are confident in our future collaboration and look forward to supporting Biostar as it expands into international markets, bringing more innovative and advanced health solutions to a global audience.”
News of the partnership comes just weeks after Biostar listed on the Hong Kong Stock Exchange, which was acknowledged by Liu.
“Congratulations to Biostar on their successful listing. The successful listing of Biostar is an exhilarating milestone that showcases the relentless efforts and remarkable achievements of Biostar in the biotech field.”
This was echoed by Biostar chair Li Tang, who said, “As a biopharmaceutical company driven by synthetic biology technology, Biostar is committed to developing innovative oncology drugs.
“Our successful listing is a major milestone in our development and a new beginning. Going forward, we will continue to focus on research and innovation, bring more innovative drug products to market, and extend our current products to more patients, contributing significantly to the health and wellness sector.”
Phase I recruitment
News of the collaboration also comes a month after Biostar completed recruitment for a US Phase I trial examining Utidelone, a microtubule inhibitor made through microbial fermentation process, as a cancer therapy.
This study includes various sites across the US, such as the Sarah Cannon Research Institute, the University of Southern California, and Washington University in St. Louis.
Chinese authorities approved Utidelone in 2021. Earlier this month, Biostar partnered with Baheal Intelligent Technology to accelerate the commercialization of the product in China.
DepositPhotos/rochu_2008